文献速递肝病消化道肿瘤与早癌

索拉非尼与HCV相关肝细胞癌肿瘤生长及肝功能恶化减慢相关

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2021-05-27

该研究基于国际临床试验的纵向数据,采用联合模型同时分析生存与肿瘤进展,量化接受索拉非尼治疗晚期肝细胞癌患者的肿瘤生长速率及其与生存的关系。结果显示,HCV血清阳性患者的肿瘤生长速率、甲胎蛋白上升及肝功能下降均显著低于阴性者,且在两个独立患者组中得到重复验证。

要点

  • 索拉非尼治疗中,HCV阳性患者肿瘤负荷增长速率及甲胎蛋白上升显著低于阴性患者。
  • 基线肿瘤负荷高与死亡风险增加相关。
  • 肿瘤负荷日增长超过0.12 mm或12%速率者中位生存234天,低于该速率者384天。

核心结论

  • 索拉非尼治疗晚期肝细胞癌的生存获益主要与HCV感染患者肿瘤生长速率及肝功能恶化减慢相关。

研究设计与样本

  • 基于国际临床试验的纵向数据,采用联合模型同时分析生存与肿瘤进展,估算肿瘤负荷及血清甲胎蛋白的生长速率。

主要发现

  • 基线肿瘤负荷高与死亡风险增加相关。
  • 研究结束时仍存活者的肿瘤负荷进展远低于研究期间死亡者。
  • 总体平均肿瘤负荷变化为0.12 mm/天,绝对生长速率3.6 mm/月,中位倍增时间665天。
  • 肿瘤负荷日增长超过0.12 mm或12%速率者中位生存234天,低于该速率者384天。
  • HCV血清阳性者的肿瘤生长速率、甲胎蛋白上升及肝功能下降速率均显著低于阴性者,结果在两个独立患者组中重复验证。

临床怎么用

  • 对于接受索拉非尼治疗的晚期肝细胞癌患者,HCV血清阳性者可能从肿瘤生长及肝功能恶化减慢中获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Sorafenib has been the standard of care for patients with advanced hepatocellular carcinoma and although immunotherapeutic approaches are now challenging this position, it retains an advantage in HCV-seropositive patients. We aimed to quantify the rate of tumour progression in patients receiving sorafenib and relate this figure to survival, both overall, and according to viral status. METHODS: Using serial data from an international clinical trial we applied a joint model to combine survival and progression over time in order to estimate the rate of tumour growth as assessed by tumour burden and serum alpha-fetoprotein, and the impact of treatment on liver function. RESULTS: High tumour burden at baseline was associated with an increased risk of death. In patients still alive at the end of the study, the progression in relation to tumour burden was very low compared to those who died within the study. Overall, the change in mean tumour burden was 0.12 mm per day or an absolute growth rate of 3.6 mm/month. Median doubling time was 665 days. For those who progressed above 0.12 mm per day or the 12% rate, median survival was 234 days compared to 384 days if the rate was below 12%. Tumour growth rate and serum alpha-fetoprotein rise were significantly lower in those who were HCV seropositive as was the rate of decline in liver function. These results were replicated in 2 independent patient groups. CONCLUSION: Our analysis suggests that sorafenib treatment is associated with improved survival in patients with advanced hepatocellular carcinoma mainly by decreasing the rate of tumour growth and liver function deterioration among patients with HCV infection. LAY SUMMARY: Among patients receiving sorafenib for advanced hepatocellular carcinoma the rate of tumour growth (as assessed by changes in tumour size and the biomarker alpha-fetoprotein) and the deterioration of liver function is less in those who have the hepatitis C virus, than in those who do not.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kolamunnage-Dona R, Berhane S, Potts H, et al. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol. 2021. PMID: 34052255. doi:10.1016/j.jhep.2021.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。